title: Low-dose naloxone provides an abuse-deterrent effect to buprenorphine.
abstract: In developmental research, plasma buprenorphine concentrations comparable to a 2 mg buprenorphine-naloxone (BN) sublingual tablet have been achieved with a 0.75 mg dose of BN buccal film, a small, bioerodible polymer film for application to mucosal membranes. This was a randomized, double-blind, placebo-controlled, single-dose, four-period crossover study in opioid-dependent subjects with chronic pain receiving >100 mg oral morphine equivalents daily who experienced withdrawal following a naloxone challenge dose. The objective of the study was to determine if intravenous (IV) naloxone doses of 0.1 and 0.2 mg would produce a withdrawal response when coadministered with a 0.75 mg IV dose of buprenorphine. Fifteen subjects receiving 90-1,260 mg oral morphine equivalents per day enrolled and completed the study. Precipitated withdrawal occurred in 13% (2/15) of placebo-treated subjects and 47% (7/15) of buprenorphine-treated subjects. When combined with the 0.75 mg dose of buprenorphine, a 0.1 mg dose of naloxone increased the incidence of precipitated withdrawal to 60%, and a 0.2 mg dose of naloxone increased the incidence to 73%. By 15 minutes postdose, the mean change in Clinical Opioid Withdrawal Scale (COWS) score from predose was 3.0 for placebo, 6.9 for buprenorphine, 9.8 for BN 0.1 mg, and 12.4 for BN 0.2 mg. The mean COWS score with each active treatment was significantly greater than placebo (P<0.001), and the mean COWS score for each of the naloxone-containing treatments was significantly greater than for buprenorphine alone (P<0.001). Naloxone doses as low as 0.1 mg added an abuse-deterrent effect to a 0.75 mg IV dose of buprenorphine.
authors.affiliation: PRA Health Sciences, Salt Lake City, UT, USA.
authors.forename: Lynn R
authors.initials: LR
authors.lastname: Webster
authors.affiliation: PRA Health Sciences, Salt Lake City, UT, USA.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Smith
authors.affiliation: Biometrical Solutions LLC, Raleigh, NC, USA.
authors.forename: Cemal
authors.initials: C
authors.lastname: Unal
authors.affiliation: BioDelivery Sciences International, Inc., Raleigh, NC, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Finn
keywords: abuse-deterrent; buprenorphine; intravenous; nalox-one; opioid dependence; withdrawal symptoms